Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASRT NASDAQ:CNTX NASDAQ:FBRX NASDAQ:FNCH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASRTAssertio$0.81+5.3%$0.72$0.51▼$1.38$78.05M0.28323,829 shs280,582 shsCNTXContext Therapeutics$0.85-0.9%$0.74$0.49▼$2.59$76.44M1.89199,769 shs90,745 shsFBRXForte Biosciences$11.23+0.6%$11.32$4.11▼$28.68$139.59M2.9163,287 shs114,592 shsFNCHFinch Therapeutics Group$13.00+6.1%$12.69$10.15▼$15.85$20.88M1.192,182 shs287 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASRTAssertio-1.38%-0.96%+6.21%+13.45%-36.36%CNTXContext Therapeutics+0.06%-4.95%+1.18%+39.34%-65.60%FBRXForte Biosciences-0.89%-5.10%-4.04%+33.17%+80,769.57%FNCHFinch Therapeutics Group-3.57%+1.83%-2.00%-10.11%+0.41%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASRTAssertio2.193 of 5 stars3.22.00.00.02.30.81.3CNTXContext Therapeutics3.5502 of 5 stars3.64.00.00.03.21.71.3FBRXForte Biosciences2.7768 of 5 stars3.53.00.00.02.61.70.6FNCHFinch Therapeutics Group0.3111 of 5 stars0.03.00.00.00.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASRTAssertio 2.33Hold$2.38192.85% UpsideCNTXContext Therapeutics 3.17Buy$5.25516.05% UpsideFBRXForte Biosciences 3.00Buy$68.00505.52% UpsideFNCHFinch Therapeutics Group 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest FNCH, FBRX, CNTX, and ASRT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/25/2025ASRTAssertioZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeHold ➝ Strong Sell8/18/2025FBRXForte BiosciencesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$75.008/18/2025FBRXForte BiosciencesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$75.008/15/2025FBRXForte BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$61.008/12/2025ASRTAssertioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$3.50 ➝ $3.008/7/2025CNTXContext TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.00 ➝ $4.008/7/2025CNTXContext TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.006/26/2025CNTXContext TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$4.50 ➝ $4.006/24/2025FBRXForte BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$61.00(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASRTAssertio$124.96M0.62$0.05 per share15.90$0.97 per share0.84CNTXContext TherapeuticsN/AN/AN/AN/A$0.92 per shareN/AFBRXForte BiosciencesN/AN/AN/AN/A$7.93 per shareN/AFNCHFinch Therapeutics GroupN/AN/AN/AN/A$14.25 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASRTAssertio-$21.58M-$0.45N/A27.03N/A-36.97%-38.19%-15.45%11/10/2025 (Estimated)CNTXContext Therapeutics-$26.73M-$0.36N/AN/AN/AN/A-38.80%-37.53%11/5/2025 (Estimated)FBRXForte Biosciences-$35.48M-$16.29N/AN/AN/AN/A-85.38%-72.34%11/13/2025 (Estimated)FNCHFinch Therapeutics Group-$74.75M-$8.82N/A∞N/AN/A-69.14%-26.92%N/ALatest FNCH, FBRX, CNTX, and ASRT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025FBRXForte Biosciences-$1.21-$0.96+$0.25-$0.96N/AN/A8/11/2025Q2 2025ASRTAssertio-$0.10-$0.17-$0.07-$0.17$27.86 million$29.22 million8/6/2025Q2 2025CNTXContext Therapeutics-$0.06-$0.09-$0.03-$0.09N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASRTAssertioN/AN/AN/AN/AN/ACNTXContext TherapeuticsN/AN/AN/AN/AN/AFBRXForte BiosciencesN/AN/AN/AN/AN/AFNCHFinch Therapeutics GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASRTAssertio0.421.591.34CNTXContext TherapeuticsN/A19.0919.09FBRXForte BiosciencesN/A11.7411.74FNCHFinch Therapeutics GroupN/A3.873.87Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASRTAssertio48.96%CNTXContext Therapeutics14.03%FBRXForte Biosciences77.63%FNCHFinch Therapeutics Group21.77%Insider OwnershipCompanyInsider OwnershipASRTAssertio4.00%CNTXContext Therapeutics2.80%FBRXForte Biosciences5.90%FNCHFinch Therapeutics Group44.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASRTAssertio2096.24 million92.39 millionOptionableCNTXContext Therapeutics789.70 million87.19 millionNot OptionableFBRXForte Biosciences512.43 million11.70 millionOptionableFNCHFinch Therapeutics Group1901.61 million885,000No DataFNCH, FBRX, CNTX, and ASRT HeadlinesRecent News About These CompaniesCritical Comparison: Finch Therapeutics Group (NASDAQ:FNCH) vs. Protalix BioTherapeutics (NYSE:PLX)August 26 at 2:08 AM | americanbankingnews.comFNCH - Finch Therapeutics Group Inc Price vs Fair Value - MorningstarJuly 4, 2025 | morningstar.comMFNCH Finch Therapeutics Group, Inc. - Seeking AlphaJune 24, 2025 | seekingalpha.comArquitos Capital's Largest Holdings For Q1 2025May 1, 2025 | seekingalpha.comArquitos Capital Management Q4 2024 CommentaryFebruary 5, 2025 | seekingalpha.comFinch Therapeutics Group, Inc.: Finch Announces Delisting from Nasdaq and SEC DeregistrationOctober 23, 2024 | finanznachrichten.deFinch Therapeutics announces Nasdaq delisting, SEC deregistrationOctober 22, 2024 | markets.businessinsider.comFinch Therapeutics Group to Delist from NasdaqOctober 22, 2024 | markets.businessinsider.comFinch Announces Delisting from Nasdaq and SEC DeregistrationOctober 21, 2024 | globenewswire.comFinch Therapeutics Gr (OTC:FNCH) Stock Quotes, Forecast and News SummaryOctober 5, 2024 | benzinga.comFinch wins US jury trial against Ferring over fecal-transplant patentsAugust 10, 2024 | reuters.comIt is likely that Finch Therapeutics Group Inc (FNCH) Stock will grow upMay 25, 2024 | bovnews.comBFinch Therapeutics Group (NASDAQ: FNCH)April 14, 2024 | fool.comJeffery A. Smisek Sells 6,642 Shares of Finch Therapeutics Group, Inc. (NASDAQ:FNCH) StockMarch 31, 2024 | insidertrades.comFNCH Stock Earnings: Finch Therapeutics Gr Reported Results for Q4 2023March 25, 2024 | investorplace.comFinch Therapeutics Group Inc (FNCH)March 7, 2024 | investing.comFinch Therapeutics Gr Stock (NASDAQ:FNCH), Short Interest ReportFebruary 22, 2024 | benzinga.comFinch Therapeutics Group Inc FNCHNovember 5, 2023 | morningstar.comMAnalysts Are Bullish on These Healthcare Stocks: Nuvation Bio (NUVB), Finch Therapeutics Group (FNCH)August 21, 2023 | markets.businessinsider.comFinch Therapeutics Group, Inc.: Finch Announces Reverse Stock Split of Common StockJune 9, 2023 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFNCH, FBRX, CNTX, and ASRT Company DescriptionsAssertio NASDAQ:ASRT$0.81 +0.04 (+5.32%) Closing price 04:00 PM EasternExtended Trading$0.81 -0.01 (-0.62%) As of 05:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.Context Therapeutics NASDAQ:CNTX$0.85 -0.01 (-0.91%) Closing price 04:00 PM EasternExtended Trading$0.85 +0.00 (+0.21%) As of 04:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.Forte Biosciences NASDAQ:FBRX$11.23 +0.07 (+0.63%) Closing price 04:00 PM EasternExtended Trading$11.20 -0.03 (-0.22%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.Finch Therapeutics Group NASDAQ:FNCH$13.00 +0.75 (+6.12%) As of 03:58 PM EasternFinch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CrowdStrike at a Crossroads: AI Halo vs. Risks NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It NIO Just Got Its Second Upgrade of the Month, and It’s Big As Bitcoin Falls and Ethereum Rallies, Coinbase Stock Comes Back Williams-Sonoma Q2 Results Prove Its Buy-and-Hold Quality Okta: Market Comes to a Boil, Explosive Upside Is Possible MongoDB Roars Back to Life: It’s Not Too Late to Buy More Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access